TKT and lung carcinoma: Monoclonal antibodies targeted to EGFR and small-molecule TK inhibitors (erlotinib, gefitinib, afatinib, dacomitinib, and osimertinib) responseshave extended the lives of lung cancer patients harboring EGFR-TKI-sensitizing mutations.